


Meso Scale Discovery[®]

MULTI-ARRAY[®] Assay System

Human IL-1 α Assay
Ultra-Sensitive Kit

1-Plate Kit	K151AFC-1
5-Plate Kit	K151AFC-2
25-Plate Kit	K151AFC-4



Meso Scale Discovery Meso Scale Discovery Meso Scale Discovery Meso Scale Discovery Meso Scale Discovery Meso Scale Discovery Meso Scale Di



MSD MULTI-ARRAY Assay

Ultra-Sensitive Kit

Human IL-1 α Assay

This package insert must be read in its entirety before using this product.

FOR RESEARCH USE ONLY.

NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES.

Meso Scale Discovery, Meso Scale Diagnostics, www.mesoscale.com, MSD, MSD (design), Discovery Workbench, Quickplex, Multi-Array, Multi-Spot, Sulfo-Tag and Sector are trademarks of Meso Scale Diagnostics, LLC.
© 2009 Meso Scale Discovery a division of Meso Scale Diagnostics, LLC. All rights reserved.

Table of Contents

table of contents

Introduction.....	4
Principle of the Assay	5
Reagents Supplied	6
Required Material and Equipment – not supplied	6
Safety	6
Reagent Preparation	7
Assay Protocol.....	9
Analysis of Results	9
Typical Standard Curve	10
Sensitivity	10
Spike Recovery	11
Linearity	11
Samples.....	12
References	12
Summary Protocol	15
Plate Diagrams	17

Ordering Information

Ordering information

MSD Customer Service

Phone: 1-301-947-2085
Fax: 1-301-990-2776
Email: CustomerService@mesoscale.com

Meso Scale Discovery

A division of Meso Scale Diagnostics, LLC.
9238 Gaither Road
Gaithersburg, MD 20877 USA
www.mesoscale.com

Introduction

introduction

Interleukin-1 (IL-1) was one of the first cytokines discovered; it is comprised of two distinct proteins, IL-1 α and IL-1 β . IL-1 α is a cytokine involved in the response associated with defense against infection, inflammatory process and hematopoiesis. IL-1 together with an antigen or mitogen functions as a costimulator of T cell proliferation. Synthesized as a biologically active precursor molecule without a signal peptide,^[1] most IL-1 α (in precursor form) remains in the cytosol while some is transported to the cell surface membrane of many cells, particularly monocytes and B lymphocytes.^[2-3] In general, IL-1 α is not found in the circulation or in body fluids except in severe disease states where the cytokine may be released from dying cells.^[4] After cell death, IL-1 α precursor is released and can be cleaved by extracellular proteases.^[5]

The action of IL-1 is mediated through receptors IL-1 RI and IL-1 RII plus IL-1 RAcP, a non-binding receptor accessory protein. IL-1 RI is found in low number on nearly all cells while IL-1 RII is primarily found on neutrophils, monocytes and β -lymphocytes.^[2] Signaling occurs only when IL-1 is complexed to IL-1 RI; IL-1 RI and IL-1 RAcP then work together to activate the NF- κ B pathway.^[6-11] IL-1 binds to IL-1 RII but does not initiate signaling; therefore IL-1 RII plays a role in negative feedback.^[12-14] Serum contains soluble forms of both IL-1 RI and IL-1 RII. IL-1Ra (IL-1 receptor antagonist) binds to the soluble form of IL-1 RI and competes with IL-1. When IL-1 displaces IL-1Ra on the soluble form of IL-1 RI, the action of IL-1 is enhanced.^[2, 15-16] The soluble form of IL-1 RII has a much lower affinity for IL-1Ra, which intensifies its antagonist activity.

Most cell lines, in particular epithelial cells and tumor cell lines, contain constitutive levels of IL-1 α which has also been shown to be critical for several IFN- γ activities.^[17-18] Overproduction of IL-1 α is thought to play a role in viral, bacterial, fungal and parasitic infections; leukemias; asthma; Alzheimer's disease and autoimmune disorders.^[19]

Principle of the Assay

principle of the assay

MSD[®] assays provide a rapid and convenient method for measuring the levels of protein targets within a single small-volume sample. The assays are available in both singleplex and multiplex formats. The antibody for a specific protein target is coated on one electrode (or “spot”) per well. The Human IL-1 α Assay detects IL-1 α in a sandwich immunoassay format (Figure 1). For this assay, MSD provides a Cytokine Panel 14 plate that has been pre-coated with capture antibodies on spatially distinct spots. The position of IL-1 α capture antibody is indicated in Figure 1 and on the plate packaging. The user adds the sample and a solution containing the labeled detection antibody— anti-IL-1 α labeled with an electrochemiluminescent compound, MSD SULFO-TAG[™] label—over the course of one or more incubation periods. IL-1 α in the sample binds to capture antibody immobilized on the working electrode surface; recruitment of the labeled detection antibody by bound IL-1 α completes the sandwich. The user adds an MSD read buffer that provides the appropriate chemical environment for electrochemiluminescence and loads the plate into an MSD SECTOR[®] instrument for analysis. Inside the SECTOR instrument, a voltage applied to the plate electrodes causes the labels bound to the electrode surface to emit light. The instrument measures intensity of emitted light to afford a quantitative measure of IL-1 α present in the sample.




Figure 1. Spot diagram showing placement of analyte capture antibody on Cytokine Panel 14 Plate. The numbering convention for the different spots is maintained in the software visualization tools, on the plate packaging, and in the data files. A unique bar code label on each plate allows complete traceability back to MSD manufacturing records.

Reagents Supplied

reagents supplied

Product Description	Storage	Quantity per Kit		
		K151AFC-1	K151AFC-2	K151AFC-4
MULTI-SPOT [®] 96-well 4 Spot Cytokine Panel 14 US Plate(s) N45036A-1	2–8°C	1 plate	5 plates	25 plates
SULFO-TAG [™] Anti-hIL-1 α Antibody ¹ (50X)	2–8°C	1 vial (75 μ L)	1 vial (375 μ L)	5 vials (375 μ L ea)
Human IL-1 α Calibrator (1 μ g/mL)	\leq -70°C	1 vial (15 μ L)	5 vials (15 μ L ea)	25 vials (15 μ L ea)
Diluent 2 R51BB-4 (8 mL) R51BB-3 (40 mL)	\leq -10°C	1 bottle (8 mL)	1 bottle (40 mL)	5 bottles (40 mL ea)
Diluent 3 R51BA-4 (5 mL) R51BA-5 (25 mL)	\leq -10°C	1 bottle (5 mL)	1 bottle (25 mL)	5 bottles (25 mL ea)
Read Buffer T (4X) R92TC-3 (50 mL) R92TC-2 (200 mL)	RT	1 bottle (50 mL)	1 bottle (50 mL)	2 bottles (200 mL ea)

Required Materials and Equipment - not supplied

required materials and equipment — not supplied

- Deionized water for diluting concentrated buffers
- 50 mL tubes for reagent preparation
- 15 mL tubes for reagent preparation
- Microcentrifuge tubes for preparing serial dilutions
- Phosphate buffered saline plus 0.05% Tween-20 (PBS-T) for plate washing
- Appropriate liquid handling equipment for desired throughput, capable of dispensing 10 to 150 μ L into a 96-well microtiter plate
- Plate washing equipment: automated plate washer or multichannel pipette
- Adhesive plate seals
- Microtiter plate shaker

Safety

safety

Safe laboratory practices and personal protective equipment such as gloves, safety glasses, and lab coats should be used at all times during the handling of all kit components. All hazardous samples should be handled and disposed of properly, in accordance with local, state, and federal guidelines.

¹ Some SULFO-TAG labeled detection antibodies may be light-sensitive, so they should be stored in the dark.

VI Reagent Preparation

reagent preparation

Bring all reagents to room temperature and thaw the Calibrator stock on ice.

Important: Upon first thaw, separate Diluent 2 and Diluent 3 into aliquots appropriate to the size of your assay needs. These diluents can go through up to three freeze-thaw cycles without significantly affecting the performance of the assay.

Prepare Calibrator and Control Solutions

Calibrator for the Human IL-1 α assay is supplied at 400-fold higher concentration than the recommended highest calibrator. Prepare a diluted stock Calibrator by diluting the stock Calibrator 100-fold in Diluent 2. MSD recommends the preparation of an 8-point standard curve consisting of at least 2 replicates of each point. Each well requires 25 μ L of Calibrator. For the assay, MSD recommends 4-fold serial dilution steps and Diluent 2 alone for the 8th point:

Standard	IL-1 α (pg/mL)	Dilution Factor
100X Stock	1000000	
Dil. Stock Cal.	10000	100
STD-01	2500	4
STD-02	625	4
STD-03	156	4
STD-04	39	4
STD-05	9.8	4
STD-06	2.4	4
STD-07	0.61	4
STD-08	0	n/a

To prepare this 8-point standard curve for up to 4 replicates:

- 1) Prepare the diluted stock Calibrator by transferring 10 μ L of the Human IL-1 α stock Calibrator to 990 μ L Diluent 2.
- 2) Prepare the highest Calibrator point (STD-01) by transferring 50 μ L of the Human IL-1 α diluted stock Calibrator to 150 μ L Diluent 2. Repeat 4-fold serial dilutions 6 additional times to generate 7 Calibrators.
- 3) The recommended 8th Standard is Diluent 2 (i.e. zero Calibrator).

Notes:

- a. Alternatively, Calibrators can be prepared in the sample matrix or diluent of choice to verify acceptable performance in these matrices. In general, the presence of some protein (for example, 1% BSA) in the sample matrix is helpful for preventing loss of analyte by adsorption onto the sides of tubes, pipette tips, and other surfaces. If your sample matrix is serum-free tissue culture media, then the addition of 10% FBS or 1% BSA is recommended.
- b. The standard curve can be modified as necessary to meet specific assay requirements.

Dilution of Samples

Serum and Plasma

All solid material should be removed by centrifugation. Plasma prepared in heparin tubes commonly displays additional clotting following the thawing of the sample. Remove any additional clotted material by centrifugation. Avoid multiple freeze/thaw cycles for serum and plasma samples. Serum and plasma samples may be run neat in the MSD Human IL-1 α Assay.

Tissue Culture

Tissue culture supernatant samples may not require dilution prior to being used in the MSD Human IL-1 α Assay. If using serum-free medium, the presence of carrier protein (e.g., 1% BSA) in the solution is helpful to prevent loss of analyte to the labware. Samples from experimental conditions with extremely high levels of cytokines may require a dilution.

Other Matrices

Information on preparing samples in other matrices, including sputum, CSF, and tissue homogenates can be obtained by contacting MSD Scientific Support at 1-301-947-2025 or ScientificSupport@mesoscale.com.

Prepare Detection Antibody Solution

The Detection Antibody is provided at 50X stock of Anti-hIL-1 α Antibody. The final concentration of the working Detection Antibody Solution should be at 1X. For each plate used, dilute a 60 μ L aliquot of the stock Anti-hIL-1 α Antibody into 2.94 mL of Diluent 3.

Prepare Read Buffer

The Read Buffer should be diluted 2-fold in deionized water to make a final concentration of 2X Read Buffer T. Add 10 mL of 4X Read Buffer T to 10 mL of deionized water for each plate.

Prepare MSD Plate

This plate has been pre-coated with antibody for the analyte shown in Figure 1. The plate can be used as delivered; no additional preparation (e.g., pre-wetting) is required. The plate has also been exposed to a proprietary stabilizing treatment to ensure the integrity and stability of the immobilized antibodies.

VII Assay Protocol

assay protocol

1. **Addition of Diluent 2:** Dispense 25 μL of Diluent 2 into each well. Seal the plate with an adhesive plate seal and incubate for 30 min with vigorous shaking (300–1000 rpm) at room temperature.
2. **Addition of the Sample or Calibrator:** Dispense 25 μL of sample or Calibrator into separate wells of the MSD plate. Seal the plate with an adhesive plate seal and incubate for 2 hours with vigorous shaking (300–1000 rpm) at room temperature.
3. **Wash and Addition of the Detection Antibody Solution:** Wash the plate 3X with PBS-T. Dispense 25 μL of the 1X Detection Antibody Solution into each well of the MSD plate. Seal the plate and incubate for 2 hours with vigorous shaking (300–1000 rpm) at room temperature.
4. **Wash and Read:** Wash the plate 3X with PBS-T. Add 150 μL of 2X Read Buffer T to each well of the MSD plate. Analyze the plate on the SECTOR Imager. Plates may be read immediately after the addition of Read Buffer.

Notes

Shaking a 96-well MSD plate typically accelerates capture at the working electrode.

Bubbles in the fluid will interfere with reliable reading of plate. Use reverse pipetting techniques to insure bubbles are not created when dispensing the Read Buffer.

VIII Analysis of Results


analysis of results

The Calibrators should be run in duplicate to generate a standard curve. The standard curve is modeled using least squares fitting algorithms so that signals from samples with known levels of the analyte of interest can be used to calculate the concentration of analyte in the sample. The assays have a wide dynamic range (3–4 logs) which allows accurate quantitation in many samples without the need for dilution. The MSD Discovery Workbench[®] analysis software utilizes a 4-parameter logistic model (or sigmoidal dose-response) and includes a $1/Y^2$ weighting function. The weighting function is important because it provides a better fit of data over a wide dynamic range, particularly at the low end of the standard curve.

IX Typical Standard Curve

typical standard curve

The following standard curve is an example of the dynamic range of the assay. The actual signals may vary and a standard curve should be run for each set of samples and on each plate for the best quantitation of unknown samples.



X Sensitivity

sensitivity

The lower limit of detection (LLOD) is the calculated concentration of the signal that is 2.5 standard deviations over the zero calibrator. The value below represents the average LLOD over multiple kit lots.

	IL-1α
LLOD (pg/mL)	0.12

XI Spike Recovery

spike recovery

Human serum and EDTA plasma pooled samples were spiked with Calibrator at multiple values throughout the range of the assay. Each spike was done in ≥ 3 replicates. An average of two serum and three EDTA plasma are shown here. Results of spike-recovery may vary based on the individual samples.

$\% \text{ Recovery} = \text{measured} / \text{expected} \times 100$

Sample	Spike Conc. (pg/mL)	Measured Conc. (pg/mL)	Measured Conc. % CV	% Recovery
Serum	0	0.14		
	20	18	4.3	92
	197	181	2.8	92
	1988	1901	5.8	96
EDTA Plasma	0	0.19		
	20	19	4.0	95
	197	182	4.0	92
	1988	1931	5.9	97

XII Linearity

linearity

Three pools each of human serum and EDTA plasma were evaluated; a representative pool of each is shown below. The pooled samples were spiked with Calibrator and then diluted with Diluent 2. The concentrations shown below have been corrected for dilution (concentration = measured \times dilution factor). Percent recovery is calculated as the measured concentration divided by the concentration of the previous dilution (expected).

$\% \text{ Recovery} = (\text{measured} \times \text{dilution factor}) / \text{expected} \times 100$

Sample	Fold Dilution	Conc. (pg/mL)	Conc. % CV	% Recovery
Serum	1	760	3.3	
	2	794	3.2	104
	4	756	4.4	95
	8	709	1.3	94
EDTA Plasma	1	677	1.6	
	2	748	0.0	110
	4	716	3.9	96
	8	689	2.4	96

XIII Samples

s a m p l e s

Eight normal human samples were measured for each of the following sample types: serum, EDTA plasma, and heparin plasma.

		IL-1 α (pg/mL)
Serum	Min	<LLOD
	Max	0.94
	Median	0.14
EDTA Plasma	Min	<LLOD
	Max	1.9
	Median	0.95
Heparin Plasma	Min	<LLOD
	Max	<LLOD
	Median	<LLOD

XIV References

r e f e r e n c e s

1. Mosley B, Urdal DL, Prickett KS, Larsen A, Cosman D, Conlon PJ, Gillis S, Dower SK. The interleukin-1 receptor binds the human interleukin-1 alpha precursor but not the interleukin-1 beta precursor. *J Biol Chem*. 1987 Mar 5;262(7):2941-4.
2. Dinarello CA. The interleukin-1 family: 10 years of discovery. *FASEB J*. 1994 Dec;8(15):1314-25.
3. March CJ, Mosley B, Larsen A, Cerretti DP, Braedt G, Price V, Gillis S, Henney CS, Kronheim SR, Grabstein K, et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. *Nature*. 1985 Jun 20-26;315(6021):641-7.
4. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. *Nat Med*. 2007 Jul;13(7):851-6.
5. Kobayashi Y, Oppenheim JJ, Matsushima K. Human pre-interleukin 1 alpha and beta: structural features revealed by limited proteolysis. *Chem Pharm Bull (Tokyo)*. 1991 Jun;39(6):1513-7.
6. Sims JE, Acres RB, Grubin CE, McMahan CJ, Wignall JM, March CJ, Dower SK. Cloning the interleukin 1 receptor from human T cells. *Proc Natl Acad Sci U S A*. 1989 Nov;86(22):8946-50.
7. Sims JE, March CJ, Cosman D, Widmer MB, MacDonald HR, McMahan CJ, Grubin CE, Wignall JM, Jackson JL, Call SM, et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. *Science*. 1988; Jul 29;241(4865):585-9.
8. McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL, Grubin CE, Wignall JM, Jenkins NA, Brannan CI, et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. *EMBO J*. 1991 Oct;10(10):2821-32.
9. Huang J, Gao X, Li S, Cao Z. Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. *Proc Natl Acad Science U S A*. 1997 Nov 25;94(24):12829-32.
10. Greenfeder SA, Varnell T, Powers G, Lombard-Gillooly K, Shuster D, McIntyre KW, Ryan DE, Levin W, Madison V, Ju G. Insertion of a structural domain of interleukin (IL)-1 beta confers agonist activity to the IL-1 receptor antagonist. Implications for IL-1 bioactivity. *J Biol Chem*. 1995 Sep 22;270(38):22460-6.
11. Wesche H, Korherr C, Kracht M, Falk W, Resch K, Martin MU. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). *J Biol Chem*. 1997 Mar 21;272(12):7727-31.
12. Sims JE, Giri JG, Dower SK. The two interleukin-1 receptors play different roles in IL-1 actions. *Clin Immunol Immunopathol*. 1994 Jul;72(1):9-14.

13. Sims JE, Gayle MA, Slack JL, Alderson MR, Bird TA, Giri JG, Colotta F, Re F, Mantovani A, Shanebeck K, et al. Interleukin 1 signaling occurs exclusively via the type I receptor. *Proc Natl Acad Sci U S A*. 1993 Jul 1;90(13):6155-9.
14. Colotta F, Mantovani A. Induction of the interleukin-1 decoy receptor by glucocorticoids. *Trends Pharmacol Sci*. 1994 May;15(5):138-9.
15. Svenson M, Hansen MB, Heegaard P, Abell K, Bendtzen K. Specific binding of interleukin 1 (IL-1) beta and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I. *Cytokine*. 1993 Sep;5(5):427-35.
16. Giri JG, Wells J, Dower SK, McCall CE, Guzman RN, Slack J, Bird TA, Shanebeck K, Grabstein KH, Sims JE, et al. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. *J Immunol*. 1994 Dec 15;153(12):5802-9.
17. Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y, Voronov E, Dinarello CA, Apte RN. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. *Proc Natl Acad Sci U S A*. 2004 Feb 24;101(8):2434-9.
18. Hurgin V, Novick D, Werman A, Dinarello CA, Rubinstein M. Antiviral and immunoregulatory activities of IFN-gamma depend on constitutively expressed IL-1alpha. *Proc Natl Acad Sci U S A*. 2007 Mar 20;104(12):5044-9.
19. Dinarello CA. Biologic basis for interleukin-1 in disease. *Blood*. 1996 Mar 15;87(6):2095-147.

Summary Protocol

MSD 96-well MULTI-ARRAY Human IL-1 α Assay: Ultra-Sensitive Kit

MSD provides this summary protocol for your convenience.
Please read the entire detailed protocol prior to performing the MSD Human IL-1 α Assay.

Step 1 : Sample and Reagent Preparation

Bring all reagents to room temperature and thaw the Calibrator stock on ice.

Samples may not require dilution prior to use in this assay.

Prepare calibrator solutions and standard curve.

Use the 1 μ g/mL Calibrator stock to prepare an 8-point standard curve by diluting in Diluent 2.

Note: *The standard curve can be modified as necessary to meet specific assay requirements.*

Prepare Detection Antibody Solution by diluting Detection Antibody to 1X in 3.0 mL of Diluent 3 (per plate).

Prepare 20 mL of 2X Read Buffer T by diluting 4X MSD Read Buffer T with deionized water.

SERUM OR PLASMA SAMPLES

Step 2: Add Diluent 2

Dispense 25 μ L/well Diluent 2.

Incubate at room temperature with vigorous shaking (300-1000 rpm) for 30 minutes.

Step 3: Add Sample or Calibrator

Dispense 25 μ L/well Calibrator or sample.

Incubate at room temperature with vigorous shaking (300-1000 rpm) for 2 hours.

Step 4: Wash and Add Detection Antibody Solution

Wash plate 3X with PBS-T.

Dispense 25 μ L/well 1X Detection Antibody Solution.

Incubate at room temperature with vigorous shaking (300-1000 rpm) for 2 hours.

Step 5: Wash and Read Plate

Wash plate 3X with PBS-T.

Dispense 150 μ L/well 2X Read Buffer T.

Analyze plate on SECTOR Imager instrument.

